What Glucose 30% Braun Treats: Main Uses and Benefits

Glucose 30% Braun is a highly concentrated source of carbohydrate energy, commonly used to address acute metabolic energy deficits and provide intensive nutritional support. It is applied in clinical settings that involve acute or unstable symptom patterns. Concentrated glucose solutions are used as a source of calories for patients requiring parenteral nutrition.

This preparation is relevant for managing symptomatic hypoglycemia (low blood sugar), supporting patients with systemic energy deprivation or malnutrition, and may assist with conditions where a protein-sparing effect is appropriate. It is commonly used to help with symptoms related to increased neurological or muscular activity (e.g., confusion, tremors) and severe fatigue or lethargy.

“By providing essential fuel, this solution assists with maintaining functional stability by easing distress during periods of acute metabolic stress.”

The therapeutic benefit is delivering a high caloric load in minimal fluid volume, which supports the patient during difficult episodes by easing distress and contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Support for Acute Neuro-Metabolic Distress The solution is applied when symptoms related to functional stress or systemic imbalance interfere with daily functioning, providing supportive relief when short-term symptomatic assistance is needed.

Who Can and Cannot Use Glucose 30% Braun?

The official eligibility profile for Glucose 30% Braun is defined by government regulatory agencies based on the patient's existing metabolic and fluid status. The populations are categorized into groups permitted for use, those requiring conditional use, and those for whom use is strictly contraindicated.

---

Absolute Contraindications

Use is contraindicated in patients with clinically significant hyperglycemia, hyperosmolar coma, and uncompensated diabetes mellitus. It must also be avoided in individuals with severe fluid overload conditions, including extracellular hyperhydration, pulmonary oedema, and metabolic acidosis. Furthermore, individuals with uncompensated cardiac failure or severe renal insufficiency leading to oliguria or anuria are strictly excluded.

---

Age and Conditional Use Restrictions

Adults and adolescents (from 15 years) are permitted for standard use. However, use in older adults requires caution due to the higher prevalence of renal or cardiac conditions. Children and infants are restricted to special care settings because of risks like hyponatraemia. Use also requires caution in patients with non-severe impaired glucose tolerance or severe malnutrition (refeeding syndrome risk). For pregnancy and breastfeeding, the decision to administer the solution is at the discretion of the prescribing physician and requires careful monitoring.

Interactions with other medicines and products

The official regulatory interaction profile for concentrated Dextrose solution is structured around its osmotic activity, metabolic role, and physical compatibility. The primary constraint is the prohibition of simultaneous administration with blood or blood products through the same intravenous line; this timing-based restriction is necessary to prevent documented physical incompatibility issues such as pseudoagglutination or haemolysis.

Several pharmacodynamic interactions are documented, related to the solution's effects on fluid and electrolyte balance. Co-administration with certain medicinal products, including those that increase the vasopressin effect (such as some SSRIs, narcotics, NSAIDs, and oxytocin), increases the risk of acute hyponatraemia (low serum sodium). Additionally, drugs that cause sodium retention (including corticosteroids and certain NSAIDs) may increase the risk of oedema (fluid retention).

General consideration is required when the solution is used with other medicinal products that affect glycaemic control. For procedural safety, the solution must not be mixed with other additives unless their compatibility is officially known and verified. A specific, documented population-related restriction notes that Dextrose administration should be avoided in patients with thiamine deficiency, a condition which carries the risk of precipitating Wernicke encephalopathy. The official labeling does not document any pharmacokinetic (e.g., CYP enzyme-mediated) interactions.

Mechanism of Action: Energy Pathway Modulation

Glucose 30% Braun, a hypertonic solution of D-glucose, functions as a foundational substrate for cellular metabolism. Following intravenous administration, the D-glucose molecules are rapidly transported into cells across the plasma membrane via specific glucose transporters (GLUTs). Inside the cellular cytoplasm, glucose enters the glycolytic pathway, undergoing a series of enzymatic reactions that convert it into pyruvate.

Subsequently, pyruvate feeds into the Krebs cycle and oxidative phosphorylation within the mitochondria. This cascade generates adenosine triphosphate (ATP), the primary energy currency required for all essential intracellular processes, including active transport, synthesis of macromolecules, and signal transduction. This mechanism directly fuels the central nervous system, which relies almost exclusively on glucose for its metabolic demands.

System-Level Physiological Consequence

The high solute concentration of the solution induces a significant, albeit transient, osmotic gradient within the intravascular space. This elevated osmolality triggers an immediate fluid shift, drawing free water from the interstitial and intracellular compartments into the plasma to establish osmotic equilibrium. As the D-glucose is rapidly consumed and metabolized by the peripheral tissues, this initial osmotic effect diminishes, and the remaining water is then distributed across the total body fluid volume.

Administration Guidelines

Glucose 30% Braun (Glucose 30% w/v Intravenous Infusion BP) is a high-concentration glucose solution governed by specific rules for administration.

Route and Preparation

The solution must be administered by central intravenous infusion only. Prior to use, the liquid should be inspected; it must be clear and colourless or slightly yellowish and virtually free of particles. The solution is typically used as one component of total parenteral nutrition and, in this context, must be combined with an adequate supply of amino acids, lipids, electrolytes, vitamins, and trace elements.

Dosing and Rate Limits

Dosing is determined by the patient's individual glucose and fluid needs. Strict limits apply to adults and adolescents (from 15 years of age):

Parameter	Maximum Limit (Adults/Adolescents)
Maximum Daily Dose	20 mL/kg body weight (BW) per day
Maximum Infusion Rate	0.83 mL/kg BW per hour

For a 70 kg patient, the maximum infusion rate is approximately 58 mL per hour. If the body's ability to process glucose is impaired, the dosage must be adjusted to keep blood glucose levels within a near-normal range.

Age-Specific Use and Discontinuation

For children, a 10% glucose solution is generally recommended; the use of the 30% strength requires determination of dose and rate by a specialist in pediatric medicine based on the child's age, weight, and clinical condition.

Crucially, the infusion must not be stopped suddenly. Sudden discontinuation of high glucose infusion rates must be avoided, as this may lead to low blood glucose levels. The procedure requires that the glucose infusion be tapered off gradually over a period of 30 to 60 minutes.

Research Evidence / Overview of Studies for Glucose 30% Braun

This section outlines the types of research and studies that have been conducted on concentrated Dextrose solutions, including Glucose 30% Braun. This research has explored the solution's evaluation in different metabolic situations. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

---

Evidence for Use in Symptomatic Hypoglycemia (Low Blood Sugar)

Studies involving short-term Randomized Controlled Trials (RCTs) and observational settings have examined the fundamental metabolic effect of intravenous Dextrose on blood glucose levels. Research monitored patterns related to blood glucose elevation immediately following administration. Findings described the time required for symptom changes related to acute hypoglycemia (such as confusion or tremors) following intervention. This research is consistent with the established physiological role of Dextrose in modifying plasma glucose markers.

Comparative evidence is lacking in large trials that directly compare the Dextrose 30% concentration against other lower concentrations. The research is focused on the acute physiological effect, meaning long-term effects are not fully established.

---

Evidence for Use in Parenteral Nutrition (Calorie Provision)

Evidence from Systematic Reviews and clinical guidelines has examined the role of concentrated Dextrose as a core source of carbohydrate energy for patients who require intravenous nutritional support. Studies monitored measurements showing that the high concentration of Dextrose contributed to a significant portion of the daily energy requirements for patients on TPN (Total Parenteral Nutrition). Concentrated Dextrose solutions are noted in clinical guidelines as a component where research has explored contributing to metabolic energy in TPN protocols.

It is difficult to isolate the specific findings of the concentrated Dextrose component, as studies usually evaluate the complete TPN mixture. Data are still emerging regarding the long-term impact of this specific concentration on certain metabolic markers.

---

What is Still Uncertain About Glucose 30% Braun Research

The research landscape contains key limitations. Comparative evidence is lacking in trials directly comparing the Dextrose 30% solution against other concentrations or IV fluids. For the acute indications, follow-up durations were limited, and long-term effects are not fully established. Additionally, data for certain groups remain insufficient, meaning findings for some special populations, such as during pregnancy, have limited information.

Key Studies & References

1. Total Parenteral Nutrition - StatPearls (General guidance on dextrose as carbohydrate source in TPN)

Common questions about Glucose 30% Braun (FAQ)

Q: What is Glucose 30% Braun and what is it used for?

Glucose 30% Braun is a solution of the simple sugar glucose (also known as dextrose) that is given intravenously (into a vein). It belongs to a group of medicines called intravenous fluids and is used for several purposes:

• To provide energy and fluid when a patient is unable to take adequate amounts orally.
• To treat hypoglycemia (low blood sugar), which is a condition where the glucose level in the blood drops too low.
• To treat specific electrolyte imbalances, such as hyperkalemia (high levels of potassium in the blood), by promoting the movement of potassium into cells when given with insulin.
• As a diluent (a solution used to mix or dissolve other medicines) for other compatible medicines that need to be administered intravenously.

Q: How is Glucose 30% Braun given?

Glucose 30% Braun is administered as an infusion directly into a vein (intravenously). A doctor or a trained nurse will administer the infusion. It is usually given into a central vein (a larger vein) because of its high concentration, which can irritate smaller, peripheral veins.

• The specific dose and infusion rate will be determined by your doctor based on your age, weight, medical condition, and blood glucose levels.
• Your blood glucose and electrolyte levels will be monitored closely during the infusion.

Q: What should I know before receiving Glucose 30% Braun?

It is important to tell your doctor or nurse if you have any pre-existing medical conditions, especially:

• Diabetes mellitus or any condition where your body has difficulty processing sugar.
• Severe dehydration without salt replacement.
• Anuria (failure of the kidneys to produce urine).
• Hyperglycemia (very high blood sugar).
• Intracranial or intraspinal hemorrhage (bleeding inside the head or spine) or if you have had a recent ischemic stroke, unless your blood sugar is low.
• Known allergy or hypersensitivity to corn or corn products, as glucose solutions can sometimes be derived from corn.

Q: What are the possible side effects of Glucose 30% Braun?

Like all medicines, Glucose 30% Braun can cause side effects, although not everybody gets them. Most side effects are related to the administration technique or giving too much fluid or sugar too quickly.

Potential side effects include:

• Hyperglycemia (high blood sugar), especially when given too quickly or in patients with impaired glucose tolerance.
• Fluid overload (hypervolemia), which can lead to swelling (edema) or, in severe cases, heart problems.
• Electrolyte disturbances, such as hypokalemia (low potassium) or hypophosphatemia (low phosphate).
• Local reactions at the injection site (if given into a peripheral vein), such as pain, irritation, vein inflammation (phlebitis), or vein clotting (thrombophlebitis).
• Injection site infection.

Tell your doctor or nurse immediately if you experience any signs of an allergic reaction (e.g., rash, itching, swelling) or any severe symptoms during or after the infusion.

Q: Can Glucose 30% Braun be used in children and the elderly?

Yes, Glucose 30% Braun can be used in both children and the elderly, but with extra caution.

• Children and infants (especially newborns) require very careful dose and rate adjustments, as they are more susceptible to fluid imbalances and rapid changes in blood sugar, which can lead to serious complications.
• Elderly patients may also require closer monitoring of their fluid status and blood glucose levels, as they are more likely to have underlying heart or kidney conditions that can affect how they handle the infusion.

In all cases, the doctor will calculate the appropriate dose based on the patient's weight, clinical condition, and individual fluid and energy needs.

Storage and Disposal of Glucose 30% Solution

The storage and disposal of this parenteral carbohydrate solution must follow official regulatory requirements to ensure product integrity and environmental safety.

---

Official Storage Conditions

Requirement	Official Instruction
Temperature	The unopened container must be stored at or not above 25, C (77 °F) and protected from freezing.
Handling	Only use if the solution is clear and colorless or slightly yellowish and the container is undamaged.
Child Safety	The medicine must be kept out of the sight and reach of children.

---

Single Use and Disposal

This product is designated for single use only. Any unused portion or waste material must be discarded immediately after use. Disposal should be performed in accordance with local requirements for pharmaceutical waste. Do not dispose of the medicine via wastewater or regular household waste.